Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 216.39
ABAX's Cash to Debt is ranked higher than
82% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. ABAX: 216.39 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: 216.39

Equity to Asset 0.85
ABAX's Equity to Asset is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. ABAX: 0.85 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.9
Current: 0.85

0.48
0.9
F-Score: 7
Z-Score: 21.32
M-Score: -2.60
WACC vs ROIC
2.98%
22.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.35
ABAX's Operating margin (%) is ranked higher than
93% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ABAX: 15.35 )
ABAX' s 10-Year Operating margin (%) Range
Min: -89.79   Max: 22.65
Current: 15.35

-89.79
22.65
Net-margin (%) 12.84
ABAX's Net-margin (%) is ranked higher than
93% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.12 vs. ABAX: 12.84 )
ABAX' s 10-Year Net-margin (%) Range
Min: -84.85   Max: 51.27
Current: 12.84

-84.85
51.27
ROE (%) 13.38
ABAX's ROE (%) is ranked higher than
89% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.59 vs. ABAX: 13.38 )
ABAX' s 10-Year ROE (%) Range
Min: -54.61   Max: 62.55
Current: 13.38

-54.61
62.55
ROA (%) 11.44
ABAX's ROA (%) is ranked higher than
93% of the 301 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. ABAX: 11.44 )
ABAX' s 10-Year ROA (%) Range
Min: -36.26   Max: 50.99
Current: 11.44

-36.26
50.99
ROC (Joel Greenblatt) (%) 45.30
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 300 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.48 vs. ABAX: 45.30 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -397.78   Max: 57.43
Current: 45.3

-397.78
57.43
Revenue Growth (3Y)(%) 6.60
ABAX's Revenue Growth (3Y)(%) is ranked higher than
74% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. ABAX: 6.60 )
ABAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 6.6   Max: 32.9
Current: 6.6

6.6
32.9
EBITDA Growth (3Y)(%) 1.90
ABAX's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. ABAX: 1.90 )
ABAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 1.9   Max: 171.4
Current: 1.9

1.9
171.4
EPS Growth (3Y)(%) -0.50
ABAX's EPS Growth (3Y)(%) is ranked higher than
74% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ABAX: -0.50 )
ABAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.2   Max: 159.6
Current: -0.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ABAX Guru Trades in Q2 2014

Joel Greenblatt 26,303 sh (+30.03%)
PRIMECAP Management 1,975,700 sh (-0.18%)
» More
Q3 2014

ABAX Guru Trades in Q3 2014

Columbia Wanger 602,000 sh (New)
Jim Simons 7,600 sh (New)
PRIMECAP Management 1,973,200 sh (-0.13%)
Joel Greenblatt 16,012 sh (-39.12%)
» More
Q4 2014

ABAX Guru Trades in Q4 2014

Paul Tudor Jones 4,900 sh (New)
Joel Greenblatt 124,964 sh (+680.44%)
Jim Simons 34,000 sh (+347.37%)
Columbia Wanger 892,800 sh (+48.31%)
PRIMECAP Management 2,022,200 sh (+2.48%)
» More
Q1 2015

ABAX Guru Trades in Q1 2015

Jim Simons Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 2,021,200 sh (-0.05%)
Columbia Wanger 735,800 sh (-17.59%)
Joel Greenblatt 29,776 sh (-76.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 60.00
ABAX's P/E(ttm) is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 60.00 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 75.93
Current: 60

10.19
75.93
Forward P/E 40.82
ABAX's Forward P/E is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 40.82 )
N/A
PE(NRI) 60.50
ABAX's PE(NRI) is ranked higher than
80% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 60.50 )
ABAX' s 10-Year PE(NRI) Range
Min: 10.15   Max: 75.53
Current: 60.5

10.15
75.53
P/B 5.50
ABAX's P/B is ranked higher than
53% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. ABAX: 5.50 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 8.03
Current: 5.5

2.19
8.03
P/S 5.90
ABAX's P/S is ranked lower than
51% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. ABAX: 5.90 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 8.54
Current: 5.9

2.48
8.54
PFCF 39.80
ABAX's PFCF is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 39.80 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 39.8

21.92
101.52
POCF 33.49
ABAX's POCF is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 33.49 )
ABAX' s 10-Year POCF Range
Min: 17.34   Max: 77.91
Current: 33.49

17.34
77.91
EV-to-EBIT 34.80
ABAX's EV-to-EBIT is ranked higher than
79% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 34.80 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 68.1
Current: 34.8

10.6
68.1
PEG 6.88
ABAX's PEG is ranked higher than
91% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 6.88 )
ABAX' s 10-Year PEG Range
Min: 0.19   Max: 13.47
Current: 6.88

0.19
13.47
Shiller P/E 68.30
ABAX's Shiller P/E is ranked higher than
78% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 68.30 )
ABAX' s 10-Year Shiller P/E Range
Min: 20.75   Max: 222
Current: 68.3

20.75
222
Current Ratio 6.12
ABAX's Current Ratio is ranked higher than
88% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ABAX: 6.12 )
ABAX' s 10-Year Current Ratio Range
Min: 1.54   Max: 9.82
Current: 6.12

1.54
9.82
Quick Ratio 5.02
ABAX's Quick Ratio is ranked higher than
88% of the 293 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. ABAX: 5.02 )
ABAX' s 10-Year Quick Ratio Range
Min: 1.12   Max: 8.45
Current: 5.02

1.12
8.45
Days Inventory 108.68
ABAX's Days Inventory is ranked higher than
73% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 137.36 vs. ABAX: 108.68 )
ABAX' s 10-Year Days Inventory Range
Min: 65.4   Max: 134.23
Current: 108.68

65.4
134.23
Days Sales Outstanding 49.73
ABAX's Days Sales Outstanding is ranked higher than
85% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.63 vs. ABAX: 49.73 )
ABAX' s 10-Year Days Sales Outstanding Range
Min: 57.8   Max: 92.68
Current: 49.73

57.8
92.68

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
ABAX's Dividend Yield is ranked lower than
73% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. ABAX: 0.80 )
ABAX' s 10-Year Dividend Yield Range
Min: 0.21   Max: 0.57
Current: 0.8

0.21
0.57
Dividend Payout 0.34
ABAX's Dividend Payout is ranked higher than
93% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 0.34 )
ABAX' s 10-Year Dividend Payout Range
Min: 0.39   Max: 0.48
Current: 0.34

0.39
0.48
Yield on cost (5-Year) 0.80
ABAX's Yield on cost (5-Year) is ranked lower than
70% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.43 vs. ABAX: 0.80 )
ABAX' s 10-Year Yield on cost (5-Year) Range
Min: 0.21   Max: 0.57
Current: 0.8

0.21
0.57
Share Buyback Rate 0.40
ABAX's Share Buyback Rate is ranked higher than
91% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.20 vs. ABAX: 0.40 )
ABAX' s 10-Year Share Buyback Rate Range
Min: 0.4   Max: -10.8
Current: 0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.70
ABAX's Price/Net Cash is ranked higher than
82% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 16.70 )
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92   Max: 300
Current: 16.7

5.92
300
Price/Net Current Asset Value 10.60
ABAX's Price/Net Current Asset Value is ranked higher than
81% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 10.60 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 3.41   Max: 38.07
Current: 10.6

3.41
38.07
Price/Tangible Book 5.50
ABAX's Price/Tangible Book is ranked higher than
72% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.20 vs. ABAX: 5.50 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.86   Max: 36.9
Current: 5.5

2.86
36.9
Price/DCF (Projected) 2.70
ABAX's Price/DCF (Projected) is ranked higher than
81% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 2.70 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.7   Max: 180.9
Current: 2.7

1.7
180.9
Price/Median PS Value 1.20
ABAX's Price/Median PS Value is ranked higher than
74% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. ABAX: 1.20 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 8.88
Current: 1.2

0.31
8.88
Price/Peter Lynch Fair Value 5.80
ABAX's Price/Peter Lynch Fair Value is ranked higher than
87% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 5.80 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.52   Max: 11.31
Current: 5.8

0.52
11.31
Price/Graham Number 3.90
ABAX's Price/Graham Number is ranked higher than
84% of the 338 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ABAX: 3.90 )
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 10.96
Current: 3.9

1.42
10.96
Earnings Yield (Greenblatt) 2.90
ABAX's Earnings Yield (Greenblatt) is ranked higher than
73% of the 298 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. ABAX: 2.90 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 9.5
Current: 2.9

1.5
9.5
Forward Rate of Return (Yacktman) 12.08
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. ABAX: 12.08 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.2   Max: 55.9
Current: 12.08

-0.2
55.9

Analyst Estimate

Mar16 Mar17
Revenue(Mil) 219 244
EPS($) 1.30 1.48
EPS without NRI($) 1.30 1.48

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany,
Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market, point-of-care diagnostic instruments and consumables used in the veterinary market, and veterinary reference laboratory diagnostic and consulting services for veterinarians provided by Abaxis Veterinary Reference Laboratories (AVRL). The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Companys products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company markets and sells its products worldwide by maintaining direct sales forces and through independent distributors. It competes with Alere, Alfa Wassermann S.P.A., Johnson & Johnson (including its subsidiary, Ortho-Clinical Diagnostics, Inc.), F. Hoffmann-La Roche Ltd, Idexx Laboratories, Inc. and Heska Corporation. The Companys Piccolo products are in vitro diagnostic medical devices subj
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 
ABAXIS Announces Contract Manufacturing Agreement with SA Scientific, Ltd. Jan 13 2009 

More From Other Websites
Abaxis, Inc. to Present at the Stifel 2015 Dental & Veterinary Conference May 21 2015
Abaxis, Inc. to Present at the Stifel 2015 Dental & Veterinary Conference May 21 2015
Abaxis Disappoints with Tepid Q4; AVRL Sale May Hurt Growth - Analyst Blog May 15 2015
Abaxis (ABAX) Q4 Earnings Miss the Mark, Revenues Up Y/Y - Analyst Blog May 05 2015
Zacks Rank #5 Additions for Tuesday - Tale of the Tape May 05 2015
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 05 2015
Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference May 05 2015
ABAXIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... May 04 2015
Abaxis misses Street 4Q forecasts Apr 30 2015
Abaxis misses Street 4Q forecasts Apr 30 2015
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10%... Apr 30 2015
4:07 pm Abaxis misses by $0.10, misses on revs Apr 30 2015
ABAXIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Apr 30 2015
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10%... Apr 30 2015
Abaxis Reconfigures Executive Management Team Apr 30 2015
Abaxis Reconfigures Executive Management Team Apr 30 2015
Q4 2015 Abaxis Inc Earnings Release - After Market Close Apr 30 2015
Abaxis To Report Fourth Quarter And Fiscal Year 2015 Financial Results Thursday, April 30, 2015 Apr 21 2015
Abaxis To Report Fourth Quarter And Fiscal Year 2015 Financial Results Thursday, April 30, 2015 Apr 21 2015
Zimmer Unveils External Fixation System, Expands in Trauma - Analyst Blog Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK